P2RY12 and acute coronary syndrome: In contrast to our results, studies using platelet-rich or platelet-poor plasma from patients with acute coronary syndrome found miR-223 levels to be decreased in patients with a very low response to P2Y12 inhibitors, compared with normal responders [30,31,32].